GLP-1 Agonists With SGLT2 Inhibitors In Diabetes

2 Aug 2023 • This study conducted a post hoc analysis of the Harmony Outcomes trial, which included 9,462 patients with type 2 diabetes (T2D), established cardiovascular disease (CVD), and high glycated hemoglobin levels. The patients were randomized to receive either albiglutide or a placebo. The primary outcome was the composite of cardiovascular death, myocardial infarction (MI), or stroke.

  • The results showed that albiglutide significantly reduced the risk of the primary composite outcome compared to placebo.
  • Additionally, a meta-analysis of this trial and another study involving 13,538 patients with T2D demonstrated that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduced the risk of adverse cardiovascular events, including heart failure hospitalization, regardless of whether patients were on background sodium-glucose cotransporter-2 inhibitors (SGLT2i) or not.

In conclusion, the study suggests that treatment with GLP-1 RAs reduces the risk of adverse cardiovascular events in patients with T2D and CVD, regardless of background SGLT2i use.

Source: ACC | Read full story

Contact us

+91 9023-729662

Medflix Logo

© 2022 Plexus Professionals Network Pvt Ltd